CLINICAL ROLE -
The Role of Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancer
There are 5 available EGFR TKIs for the treatment of patients with EGFR-mutant lung cancers: gefitinib (Iressa), erlotinib (Tarceva), afatinib (Gilotrif), dacomitinib (Vizimpro), and osimertinib.
Read More
How Immunotherapy is Changing the Treatment of Small Cell Lung Cancer
Meaningful improvements in outcomes with immunotherapy in recent years are finally starting to change the tide for the first-line treatment of patients with small-cell lung cancer.